Patent Application
20200115402
The present invention refers to a process for the preparation of a mono(acyl)phosphine of the general formula I and/or a bis(acyl)phosphine of the general formula II,
wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring; R6 is H or R6 is replaced by an alkaline earth metal cation or a mixed alkali metal/alkaline earth metal cation;
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring; as well as the mono(acyl)phosphine and/or the bis(acyl)phosphine obtained by the process.
Mono and bis(acyl)phosphines are known in the state of the art as intermediates which are obtained when preparing mono and bis(acyl)phosphine oxide or mono and bis(acyl)phosphine sulfide compounds. These oxides and sulfides find diverse applications as reactive initiators in the light-induced polymerisation of ethylenically unsaturated compounds. For example, such compounds are known inter alia from U.S. Pat. Nos. 4,298,738, 4,737,593, 4,792,632, 5,218,009, 5,399,770, 5,472,992 or 5,534,559 and WO 00/32612 A1.
As the technology of the mono and/or bis(acyl)phosphine oxides is becoming increasingly important owing to the excellent photoinitiator properties of these compounds, there is also a need for highly practicable processes involving as little elaboration as possible for the preparation of the required intermediates, especially of the corresponding mono and/or bis(acyl)phosphines.
Therefore, there is a continuous need in the art for providing a competitive and reliable process for the preparation of mono and bis(acyl)phosphines. Furthermore, it is desirable to provide a process for the preparation of mono and/or bis(acyl)phosphines which avoids elaborated processing steps for obtaining the desired mono and/or bis(acyl)phosphines. In addition thereto, it is desirable to provide a process without the need of metallic sodium or lithium in combination with undesirable phosphorus compounds such as an allotrope of phosphorous, e.g. white or red phosphorus, phosphorus trichloride, alkyl or aryl phosphine, or dialkyl or diaryl phosphine, because of their volatility, bad smell, toxicity and susceptibility to air and fire. Furthermore, it is desirable to provide a process which allows the preparation of mono and/or bis(acyl)phosphines which are not accessible by the processes of the prior art.
Accordingly, it is an object of the present invention to provide a process for the preparation of mono and/or bis(acyl)phosphines. It is an even further object of the present invention to provide a competitive and reliable process for the preparation of mono and/or bis(acyl)phosphines without elaborate processing steps for obtaining the desired mono and/or bis(acyl)phosphines. It is an even further object of the present invention to provide a process for the preparation of mono and/or bis(acyl)phosphines which avoids the use of metallic sodium or lithium in combination with undesirable phosphorus compounds such as white phosphorus, red phosphorus, phosphorus trichloride, alkyl or aryl phosphine, or dialkyl or diaryl phosphine. It is another object of the present invention to provide a process which allows for the preparation of mono and/or bis(acyl)phosphines which are not accessible starting from easily available and cheap phosphorus sources a in a single step by the processes of the prior art.
The foregoing and other objects are solved by the subject matter of the present invention.
According to a first aspect of the present invention, a process for the preparation of a mono(acyl)phosphine of the general formula I and/or a bis(acyl)phosphine of the general formula II is provided,
wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring; R6 is H or R6 is replaced by an alkaline earth metal cation or a mixed alkali metal/alkaline earth metal cation,
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring; the process comprising the steps of
The inventors surprisingly found out that such a process is suitable for the preparation of mono and/or bis(acyl)phosphines and avoids elaborate processing steps for obtaining the desired mono and/or bis(acyl)phosphines. Furthermore, the process is competitive and reliable. Furthermore, the process allows the preparation of the mono and/or bis(acyl)phosphines without the use of metallic sodium or lithium in combination with undesirable phosphorus compounds such as white phosphorus, red phosphorus, phosphorus trichloride, alkyl or aryl phosphine, or dialkyl or diaryl phosphine. In addition thereto, the process allows the preparation of mono and/or bis(acyl)phosphines which are not accessible by the processes of the prior art.
Advantageous embodiments of the inventive process are defined in the corresponding sub-claims.
According to one embodiment, R1, R3 and R5 and/or R7, R9 and R11 are the same.
According to another embodiment, R1, R3 and R5 and/or R7, R9 and R11 are the same and are selected from linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl.
According to yet another embodiment, R2 and R4 and/or R8 and R10 are the same, preferably R2 and R4 and/or R8 and R10 are different from R1, R3 and R5 and/or R7, R9 and R11.
According to one embodiment, R2 and R4 and/or R8 and R10 are the same and are H.
According to another embodiment, Z is a halogen, preferably selected from fluoro, chloro, bromo and iodo, more preferably chloro.
According to yet another embodiment, the metal phosphide is selected from the group comprising Ca3P2, Zn3P2, Mg3P2, AlP, Fe3P, and mixtures thereof, preferably from the group comprising Ca3P2, Zn3P2, AlP and mixtures thereof.
According to one embodiment, the chelating agent has the capability of complexing cations such as Ca2+, Zn2+, Mg2+, AI+, Fe3+and mixtures thereof.
According to another embodiment, the chelating agent is selected from the group comprising 1,2-dimethoxyethane (DME), 1,2-diethoxyethane (DEE), 1,2-dihydroxypropane, 1,3-dihydroxypropane, 1,2-dimethoxypropane, 1,3-dimethoxypropane, glycerol, 1,3-dioxane, 1,4-dioxane, tris(2-aminoethyl)amine, tris[2-(dimethylamino)ethyl]amine, diethylene glycol dim ethyl ether (Diglyme), triethylene glycol dimethyl ether (Triglyme), N,N,N′,N′-tetramethylethylendiamine (TMEDA), ethylenediaminetetraacetic acid (EDTA) and mixtures thereof.
According to yet another embodiment, an alcohol is further added into step a), preferably an alcohol selected from the group comprising methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, tert-butanol, n-amyl alcohol, sec-amyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol, ethylenglycol, 1,2,3-propantriol, ethanolamine, diethanolamine, triethanolamine and mixtures thereof, more preferably the alcohol is selected from the group comprising tert-butanol, sec-amyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol and mixtures thereof.
According to one embodiment, an additive selected from the group comprising potassium tert-butoxide, trisodium α-DL-alanine diacetate, trimethylamine, triethylamine and mixtures thereof, is further added into step a) and/or b).
According to another embodiment, step a) is carried out at a temperature in the range from 10 to 50° C., preferably in the range from 12 to 40° C., more preferably in the range from 15 to 30° C., and most preferably in the range from 15 to 28° C. and/or step b) is carried out at a temperature in the range from −5 to 50° C., preferably in the range from 0 to 40° C., more preferably in the range from 0 to 30° C., and most preferably in the range from 0 to 28° C.
According to yet another embodiment, the process comprises a further step d) of alkylating, alkoxylating, alkenylating, alkenoxylating, arylating, acylating, carboxylating, cycloalkylating, cycloalkoxylating, arylalkoxylating, alkenylarylalkoxylating or hydroxylating and subsequently oxidizing the bis(acyl)phosphine of the general formula II obtained in step c) for obtaining a bis(acyl)phosphine of the general formula IV
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are as defined above, and R12 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-aryl al koxy, C9-C15-al kenylarylal koxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
According to one embodiment, the oxidizing is carried out by using hydrogen peroxide.
According to another embodiment, the process comprises a further step d) of alkylating, alkoxylating, alkenylating, alkenoxylating, arylating, acylating, carboxylating, cycloalkylating, cycloalkoxylating, arylalkoxylating, alkenylarylalkoxylating or hydroxylating the mono(acyl)phosphine of the general formula I obtained in step c) for obtaining the mono(acyl)phosphine of the general formula V
wherein R1, R2, R3, R4 and R5 are as defined above, and R13 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
According to a further aspect of the present invention, a mono(acyl)phosphine of the general formula I and/or a bis(acyl)phosphine of the general formula II,
wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring;
R6 is H or R6 is replaced by an alkaline earth metal cation or a mixed alkali metal/alkaline earth metal cation;
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring; obtained by a process, as defined herein, is provided.
According to another aspect of the present invention, a bis(acyl)phosphine of the general formula IV
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Ri2 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, obtained by a process, as defined herein, is provided.
According to a further aspect of the present invention, a mono(acyl)phosphine of the general formula V
wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and R13 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, obtained by a process, as defined herein, is provided.
In the following, the details and preferred embodiments of the inventive process for the preparation of the mono(acyl)phosphine and/or the bis(acyl)phosphine will be described in more detail. It is to be understood that these technical details and embodiments also apply to the inventive products, as far as applicable.
A process for the preparation of a mono(acyl)phosphine and/or a bis(acyl)phosphine is provided. It is appreciated that a mono(acyl)phosphine of the general formula I and/or a bis(acyl)phosphine of the general formula II is prepared,
wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring;
R6 is H or R6 is replaced by an alkaline earth metal cation or a mixed alkali metal/alkaline earth metal cation;
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
As regards R1, R2, R3, R4 and R5 in the general formula I and/or II, it is to be noted that they can be the same or different. Preferably, R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
The term “linear or branched C1-C20-alkyl” in the meaning of the present invention refers to a linear or branched chain alkyl group having 1 to 20 carbon atoms, and includes, for example, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec. butyl, tert. butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, 2-ethylhexyl, 1,1,3,3-tetramethylbutyl, n-heptyl, 2,4,4 trimethylpentyl, 2-ethylhexyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl and eicosyl.
The term “linear or branched C2-C8-alkenyl” in the meaning of the present invention refers to a linear or branched chain alkenyl group having 2 to 8 carbon atoms, and includes, for example, ethenyl, propenyl, butenyl, triisobutenyl, pentenyl, hexenyl, heptenyl and octenyl, preferably ethenyl or propenyl. The term “alkenyl” in the meaning of the present invention includes the cis and trans isomers.
The term “C1-C8-alkoxy” in the meaning of the present invention means that the alkoxy moiety has a linear or branched chain alkyl having 1 to 8 carbon atoms, and includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentyloxy, hexyloxy, heptyloxy and octyloxy.
The term “C2-C8-alkenyloxy” in the meaning of the present invention means that the alkenyloxy moiety has a linear or branched chain alkenyl having 2 to 8 carbon atoms, and includes, for example, ethenyloxy, propenyloxy, butenyloxy, triisobutenyloxy, pentenyloxy, hexenyloxy, heptenyloxy and octenyloxy.
The term “C3-C8-cycloalkyl” in the meaning of the present invention refers to a cyclic alkyl having 3 to 8 carbon atoms, and includes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl, preferably cyclopentyl and cyclohexyl.
The term “C6-C12-aryl” in the meaning of the present invention refers to a group containing one or more 6-membered unsaturated hydrocarbon ring(s), wherein the unsaturation is represented formally by conjugated double bonds and which may optionally be substituted at one or more carbon atoms of such ring(s) by independently selected alkyl groups, and includes, for example, phenyl, naphthyl, methylphenyl, dimethoxyphenyl, 5-isopropyl-2-methylphenyl, methylphenyl and t-butylphenyl, preferably naphthyl.
The term “C3-C8-cycloalkoxy” in the meaning of the present invention means that the cycloalkoxy moiety has a cyclic alkyl having 3 to 8 carbon atoms, and includes, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and cycloheptyloxy, preferably cyclopentyloxy and cyclohexyloxy.
The term “C7-C12-arylalkoxy” in the meaning of the present invention means that the alkoxy moiety has a linear or branched chain alkyl having 1 to 8 carbon atoms, preferably 1 or 2 carbon atoms, which is connected to C6-C12-aryl.
The term “C9-C15-alkenylarylalkoxy” in the meaning of the present invention means that the alkoxy moiety has a linear or branched chain alkyl having 1 to 8 carbon atoms, preferably 1 or 2 carbon atoms, which is connected to C6-C12-aryl, preferably C6-aryl, which is further connected to linear or branched C2-C8-alkenyl, preferably C2- alkenyl. Preferably, the alkoxy and alkenyl moieties are connected in para-position of the aryl moiety.
The term “C6-C12-arylsulfonyl” in the meaning of the present invention refers to a sulfonyl moiety having a C6-C12-aryl.
The term “4-alkylarylsulfonyl” in the meaning of the present invention refers to a sulfonyl moiety having a C6-C12-aryl, which is connected to a linear or branched C1-C20-alkyl. The alkyl moiety is connected in para-position of the aryl moiety.
The term “halogen” in the meaning of the present invention refers to fluoro, chloro, bromo or iodo.
Preferably, R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C5-alkoxy, C2-C5-alkenyloxy, C3-C5-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C5-alkoxycarbonyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R1, R2, R3, R4 and R5 in the general formula I and/or II are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C5-alkenyl, C1-C5-alkoxy, C2-C5-alkenyloxy, C3-C8-cycloalkyl and C6-C12-aryl. Preferably, R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen and, linear or branched C1-C20-alkyl. Most preferably, R1, R2, R3, R4 and R5 are the same or different and are independently selected from H and, linear or branched C1-C20-alkyl.
Thus, it is preferred that one or more of R1, R2, R3, R4 and R5 is/are H.
Additionally or alternatively, it is preferred that one or more of R1, R2, R3, R4 and R5 is/are linear or branched C1-C20-alkyl, preferably linear or branched C1-C15-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C5-alkyl, e.g. linear C1-C5-alkyl. For example, one or more of R1, R2, R3, R4 and R5 is/are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that one or more of R1, R2, R3, R4 and R5 is/are C1- or C2-alkyl, e.g. C1-alkyl.
Preferably, R1, R3 and R5 are the same. In this embodiment, R1, R3 and R5 are preferably selected from H, halogen, linear or branched C1-C5-alkyl, linear or branched C2-C5-alkenyl, C1-C5-alkoxy, C2-C5-alkenyloxy, C3-C5-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C5-alkenyl and C3-C5-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. For example, R1, R3 and R5 are the same and are selected from linear or branched C1-C8-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R1, R3 and R5 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, R1, R3 and R5 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that R1, R3 and R5 are the same and are C1- or C2-alkyl, e.g. C1-alkyl.
In one embodiment, R1, R3 and R5 are the same and are SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl.
In one embodiment, R2 and R4 are the same. In this embodiment, R2 and R4 are preferably selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. Preferably, R2 and R4 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. For example, R2 and R4 are the same and are selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R2 and R4 are the same and are H.
It is appreciated that R2 and R4 are preferably different from R1, R3 and R5. Thus, if R2 and R4 are different from R1, R3, and R5, R2 and R4 are preferably the same and are H and R1, R3 and R5 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, R2 and R4 are the same and are H and R1, R3 and R5 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that R2 and R4 are the same and are H and R1, R3 and R5 are the same and are C1- or C2-alkyl, e.g. C1-alkyl.
In one embodiment, R2 and R4 are the same and are H and R1, R3 and R5 are the same and are SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl.
As regards R7, R8, R9, R10 and R11 in the general formula II, it is to be noted that they can be the same or different. Preferably, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. More preferably, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15- alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R7, R8, R9, R10 and R11 in the general formula II are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and C6-C12-aryl. Preferably, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen and, linear or branched C1-C20-alkyl. Most preferably, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H and, linear or branched C1-C20-alkyl.
Thus, it is preferred that one or more of R7, R8, R9, R10 and R11 is/are H.
Additionally or alternatively, it is preferred that one or more of R7, R8, R9, R10 and R11 is/are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, one or more of R7, R8, R9, R10 and R11 is/are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that one or more of R7, R8, R9, R10 and R11 is/are C1- or C2-alkyl, e.g. C1-alkyl.
Preferably, R7, R9 and R11 are the same. In this embodiment, R7, R9 and R11 are preferably selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. Preferably, R7, R9 and R11 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. For example, R7, R9 and R11 are the same and are selected from linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R7, R9 and R11 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, R7, R9 and R11 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that R7, R9 and R11 are the same and are C1- or C2-alkyl, e.g. C1-alkyl.
In one embodiment, R7, R9 and R11 are the same and are SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl.
In one embodiment, R8 and R10 are the same. In this embodiment, R8 and R10 are preferably selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. Preferably, R8 and R10 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. For example, R8 and R10 are the same and are selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R8 and R10 are the same and are H.
It is appreciated that R8 and R10 are preferably different from R7, R9 and R11. Thus, if R8 and R10 are different from R7, R9 and R11, R8 and R10 are preferably the same and are H and R7, R9 and R11 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, R8 and R10 are the same and are H and R7, R9 and R11 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that R8 and R10 are the same and are H and R7, R9 and R11 are the same and are C1- or C2-alkyl, e.g. C1-alkyl.
In one embodiment, R8 and R10 are the same and are H and R7, R9 and R11 are the same and are SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloal kyl.
As regards R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula II, it is to be noted that they can be the same or different. Preferably, R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in the general formula II are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and C6-C12-aryl. Preferably, R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen and, linear or branched C1-C20-alkyl. Most preferably, R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H and, linear or branched C1-C20-alkyl.
In one embodiment, R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula II are the same. In this embodiment, R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are preferably H.
Alternatively, R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula II are different.
It is preferred that one or more of R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula II is/are H.
Additionally or alternatively, it is preferred that one or more of R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula II is/are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, one or more of R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 is/are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that one or more of R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula II is/are C1- or C2-alkyl, e.g. C1-alkyl.
Preferably, R1, R3, R5, R7, R9 and R11 in general formula II are the same. In this embodiment, R1, R3, R5, R7, R9 and R11 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. Preferably, R1, R3, R5, R7, R9 and R11 are the same and are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. For example, R1, R3, R5, R7, R9 and R11 are the same and are selected from linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R1, R3, R5, R7, R9 and R11 in general formula II are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, R1, R3, R5, R7, R9 and R11 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that R1, R3, R5, R7, R9 and R11 are the same and are C1- or C2-alkyl, e.g. C1-alkyl.
In one embodiment, R2, R4, R8 and R10 in general formula II are the same. In this embodiment, R2, R4, R8 and R10 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. For example, R2, R5, R8 and R10 are the same and are selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
In one embodiment, R2, R4, R8 and R10 are the same and are H.
It is appreciated that R2, R4, R8 and R10 are preferably different from R1, R3, R5, R7, R9 and R11. Thus, if R2, R4, R8 and R10 are different from R1, R3, R5, R7, R9 and R11, R2, R4, R8 and R10 are preferably the same and are H and R1, R3, R5, R7, R9 and R11 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl. For example, R2, R4, R8 and R10 are the same and are H and R1, R3, R5, R7, R9 and R11 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl. It is especially preferred that R2, R4, R8 and R10 are the same and are H and R1, R3, R5, R7, R9 and R11 are the same and are C1- or C2-alkyl, e.g. C1-alkyl.
As regards R6 in general formula I, it is to be noted that R6 is H. Alternatively, R6 is replaced by an alkaline earth metal cation or a mixed alkali metal/alkaline earth metal cation, preferably an alkaline earth metal cation.
Preferably, R6 in general formula I is H.
The term “alkaline earth metal cation” in the meaning of the present invention preferably refers to magnesium, calcium or strontium cations, more preferably magnesium or calcium cations and most preferably calcium cations.
The term “mixed alkali metal/alkaline earth metal cation” in the meaning of the present invention preferably refers to sodium magnesium, lithium magnesium, potassium magnesium, sodium calcium, lithium calcium, potassium calcium, sodium strontium lithium strontium or potassium strontium cations, more preferably lithium magnesium or lithium calcium cations and most preferably lithium calcium cations.
In one embodiment, the bis(acyl)phosphine of the general formula II is a bis(acyl)phosphine, in which R1, R3, R5, R7, R9 and R11 in general formula II are the same and R2, R4, R8 and R10 are the same. Preferably, R1, R3, R5, R7, R9 and R11 in general formula II are the same and are C1-alkyl and R2, R4, R8 and R10 are the same and are H.
Alternatively, the bis(acyl)phosphine of the general formula II is a bis(acyl)phosphine, in which R1, R3 and R5 in general formula II are the same, R7, R9 and R11 are the same, R2 and R4 are the same and R8 and R10 are the same. In this embodiment, R1, R3 and R5 in general formula II are different from R7, R9 and R11 and R2 and R4 are different from R8 and R10. It is thus appreciated that a mixed bis(acyl)phosphine can be prepared by the process of the present invention.
Alternatively, the bis(acyl)phosphine of the general formula II is a bis(acyl)phosphine, in which R1 and R5 in general formula II are the same, R7 and R11 are the same, R2, R3 and R4 are the same and R8, R3 and R10 are the same. In this embodiment, R1 and R5 in general formula II are different from R7 and R11 and R2, R3, R4, R8, R9 and R10 are the same or different, preferably the same.
For example, the bis(acyl)phosphine of the general formula II is a bis(acyl)phosphine, in which R1 and R5 in general formula II are the same and are chloro, R7 and R11 are the same and are methoxy, R2, R3 and R4 are the same and are H and R8, R9 and R10 are the same and are H.
Thus, it is appreciated that the process of the present invention results in the preparation of the mono(acyl)phosphine of the general formula I or the bis(acyl)phosphine of the general formula II. More preferably, a mixture of the mono(acyl)phosphine of the general formula I and the bis(acyl)phosphine of the general formula II is obtained.
It is to be noted that the formation of the mono(acyl)phosphine of the general formula I and the bis(acyl)phosphine of the general formula II can be controlled by 31P-NMR spectroscopy.
31P-NMR spectroscopy is well known to the skilled person and he will easily adapt the determination conditions according to his process equipment.
It is appreciated that the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II is prepared by a specific process, namely a process avoiding the use of metallic sodium or lithium in combination with undesirable phosphorus compounds such as white phosphorus, red phosphorus, phosphorus trichloride, alkyl or aryl phosphine, or dialkyl or diaryl phosphine.
In particular, the process is characterized in that it comprises the steps of
Accordingly, in a first step a metal phosphide is contacted with a chelating agent. It is believed that the metal cations of the metal phosphide are complexated by the chelating agent and thus this step advantageously provides a sufficient amount of phosphide anions in the following process step b).
A suitable metal phosphide is selected from the group comprising Ca3P2, Zn3P2, Mg3P2, AlP, Fe3P, Ni3P2, Sr3P2, Ba3P2, Co3P2, ScP, Ti3P4, Sn3P4, WP2, LaP, Pb3P2, BiP, and mixtures thereof or a mixed metal phosphide comprising two or more metal cations. Preferably, the metal phosphide is selected from the group comprising Ca3P2, Zn3P2, Mg3P2, AlP, Fe3P, and mixtures thereof. More preferably, the metal phosphide is selected from the group comprising Ca3P2, Zn3P2, Mg3P2, AlP and mixtures thereof. Even more preferably, the metal phosphide is selected from the group comprising Ca3P2, Zn3P2, AlP and mixtures thereof. Most preferably, the metal phosphide is selected from the group comprising Ca3P2, Zn3P2 and mixtures thereof.
It is appreciated that the mixed metal phosphide comprising two or more metal cations comprises two or more, preferably two or three, more preferably two, metal cations from periodic table group 2 through to 15. Suitable examples include, but are not limited to, iron cobalt phosphides such as Fe0.5Co0.5P, Fe0.25Co0.75P or Fe0.75Co0.25P, zirconium niobium phosphides such as Zr6.45Nb4.55P4, and mixtures thereof.
It is appreciated that calcium and zinc cations are especially accessible to be complexated by the chelating agent and thus render the phosphide anions more accessible for the following reaction and result in higher yields of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II. In one embodiment, the metal phosphide is thus Ca3P2. Alternatively, the metal phosphide is thus Zn3P2.
In view of the above, it is thus essential for the present process that the metal phosphide is contacted with a chelating agent in order to provide a sufficient amount of the phosphide anions for the following reaction. The chelating agent is not restricted to a specific chelating agent. However, it is preferred that the chelating agent has the capability of complexing Ca2+, Zn2+, Mg2+, Al+, Fe3+, Ni+, Sr2+, Ba2+, Co2+, Sc+, Ti4+, Sn4+, W2+, La+, Pb3+, Bi+, and mixtures thereof. Preferably, the chelating agent has the capability of complexing Ca2+, Zn2+, Mg2+, Al+, Fe3+ and mixtures thereof, preferably Ca2+, Zn2+, Mg2+, Al3+ and mixtures thereof, and most preferably Ca2+, Zn2+, Al3+ and mixtures thereof. For example, the chelating agent has the capability of complexing Ca2+. Alternatively, the chelating agent has the capability of complexing Zn2+.
In one embodiment, the chelating agent is selected from the group comprising 1,2-dimethoxyethane (DME), 1,2-diethoxyethane (DEE), 1,2-dihydroxypropane, 1,3-dihydroxypropane, 1,2-dimethoxypropane, 1,3-dimethoxypropane, glycerol, 1,3-dioxane, 1,4-dioxane, tris(2-aminoethyl)amine, tris[2-(dimethylamino)ethyl]amine diethylene glycol dimethyl ether (Diglyme), triethylene glycol dimethyl ether (Triglyme), N,N,N′,N′-tetramethylethylendiamine (TMEDA), ethylenediaminetetraacetic acid (EDTA) and mixtures thereof. For example, the chelating agent is selected from the group comprising 1,2-dimethoxyethane (DME), 1,2-diethoxyethane (DEE), glycerol, diethylene glycol dimethyl ether (Diglyme), triethylene glycol dimethyl ether (Triglyme), N,N,N′,N′-tetramethylethylendiamine (TMEDA), ethylenediaminetetraacetic acid (EDTA) and mixtures thereof. Preferably, the chelating agent is selected from the group comprising 1,2-dimethoxyethane (DME), 1,2-diethoxyethane (DEE), diethylene glycol dimethyl ether (Diglyme), triethylene glycol dimethyl ether (Triglyme) and mixtures thereof. More preferably, the chelating agent is selected from 1,2-dimethoxyethane (DME), 1,2-diethoxyethane (DEE), diethylene glycol dimethyl ether (Diglyme) and mixtures thereof. Most preferably, the chelating agent is 1,2-dimethoxyethane (DME) and/or 1,2-diethoxyethane (DEE), e.g. 1,2-dimethoxyethane (DME) or 1,2-diethoxyethane (DEE). In one embodiment, the chelating agent is 1,2-dimethoxyethane (DME).
It is preferred that the weight ratio of chelating agent to metal phosphide [chelating agent:metal phosphide] is from 50:1 to 2:1, more preferably from 30:1 to 3:1, even more preferably from 20:1 to 3:1 and most preferably from 10:1 to 3:1.
Step a) of the process of the present invention can be carried out over a wide temperature range. It is appreciated that a lower temperature in step a) results in a slower complexating of the metal cations by the chelating agent but improves the overall provision of phosphide anions. Thus, in order to obtain a sufficient amount of phosphide anions for the following reaction in step b) it is preferred that the process is carried out at a temperature in the range from 10 to 50° C., preferably in the range from 12 to 40° C., more preferably in the range from 15 to 30° C., and most preferably in the range from 15 to 28° C. For example, step a) is carried out at about room temperature, i.e. a temperature of about 21° C.±2° C.
In one embodiment, process step a) is carried out in the absence of further additives. This is preferably the case if the chelating agent is liquid as such, e.g. 1,2-dimethoxyethane (DME). Alternatively, process step a) is carried out in the presence of one or more additives. For example, an additive selected from the group comprising potassium tert-butoxide, trisodium α-DL-alanine diacetate, trimethylamine, trimethylamine and mixtures thereof, can be added into step a).
Additionally or alternatively, an alcohol can be further added into step a). The addition of an alcohol is advantageous in order to control the protonation of the metal phosphide and thus renders the metal phosphide more accessible (i.e. reactive) for the following reaction in process step b).
If an alcohol is added into step a), the alcohol is preferably selected from the group comprising methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, tert-butanol, n-amyl alcohol, sec-amyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol, ethylenglycol, 1,2,3-propantriol, ethanolamine, diethanolamine, triethanolamine and mixtures thereof. The overall yield is further improved if a sterically hindered alcohol is added. Thus, the alcohol is especially selected from the group comprising tert-butanol, sec-amyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol and mixtures thereof. Most preferably, the alcohol is tert-butanol, tert-amyl alcohol, 3-methyl-3-pentanol and mixtures thereof. For example, the alcohol is tert-amyl alcohol or 3-methyl-3-pentanol.
If an alcohol is added into step a), the alcohol is preferably added at the end of step a).
Process step a) is preferably carried out under mixing the components, i.e. the metal phosphide, chelating agent and optional additives and alcohol. The skilled person will adapt the mixing conditions (such as the configuration of mixing tools and mixing speed) according to his process equipment.
The following process step b) is carried out in that the mixture obtained in step a) is contacted with a compound of the general formula IIIa and/or IIIb,
wherein R1, R2, R3, R4 and R5 and/or R7, R8, R9, R10 and R11 are as defined above; Z is selected from halogen, C1-C20-alkylcarboxy, C6-C12-arylcarboxy, C1-C8-alkoxy and C6-C12-aryloxy.
With regard to the definition of the R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula IIIa and/or IIIb and preferred embodiments thereof, reference is made to the statements provided above when discussing the technical details of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II obtained by the process of the present invention.
As regards Z in in general formula IIIa and/or IIIb, it is appreciated that Z is selected from halogen, C1-C20-alkylcarboxy, C6-C12-arylcarboxy, C1-C8-alkoxy and C6-C12-aryloxy. Preferably, Z is a halogen. More preferably, Z is selected from fluoro, chloro, bromo and iodo, even more preferably chloro, bromo and iodo, still more preferably chloro and bromo. Most preferably, Z is chloro.
The term “C1-C20-alkylcarboxy” in the meaning of the present invention means that the carboxy moiety has a linear or branched chain alkyl having 1 to 20 carbon atoms, and includes, for example, methylcarboxy, ethylcarboxy, propylcarboxy, isopropylcarboxy, n-butylcarboxy, isobutylcarboxy, sec. butylcarboxy, tert. butylcarboxy, n-pentylcarboxy, isopentyl carboxy, neopentylcarboxy, hexylcarboxy, heptylcarboxy, octylcarboxy, 2-ethylhexylcarboxy, 1,1,3,3-tetramethylbutylcarboxy, n-heptylcarboxy, 2,4,4-tri methyl pentylcarboxy, 2-ethyl hexylcarboxy, octylcarboxy, nonylcarboxy, decylcarboxy, undecylcarboxy, dodecylcarboxy, tetradecylcarboxy, pentadecylcarboxy, hexadecylcarboxy, heptadecylcarboxy, octadecylcarboxy, nonadecylcarboxy and eicosylcarboxy. Accordingly, Z forms together with the carbonyl group of the compound of the general formula IIIa and/or IIIb an anhydride group.
The term “C6-C12-arylcarboxy” in the meaning of the present invention means that the carboxy moiety has a C6-C12-aryl, and includes, for example, phenylcarboxy, naphthylcarboxy, methylphenylcarboxy, dimethoxyphenylcarboxy, 5-isopropyl-2-methylphenylcarboxy, methylphenylcarboxy and t-butylphenylcarboxy, preferably naphthylcarboxy. Accordingly, Z forms together with the carbonyl group of the compound of the general formula IIIa and/or IIIb an anhydride group.
The term “C1-C8-alkoxy” in the meaning of the present invention means that the alkoxy moiety has a linear or branched chain alkyl having 1 to 8 carbon atoms, and includes, for example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy, pentyloxy, hexyloxy, heptyloxy and octyloxy. Accordingly, Z forms together with the carbonyl group of the compound of the general formula IIIa and/or IIIb an ester group.
The term “C6-C12-aryloxy” in the meaning of the present invention means that the aryloxy moiety has a C6-C12-aryl. Accordingly, Z forms together with the carbonyl group of the compound of the general formula IIIa and/or IIIb an ester group.
Thus, in one embodiment the compound of the general formula IIIa is a compound wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and C6-C12-aryl and Z is chloro. Preferably, R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen and, linear or branched C1-C20-alkyl and Z is chloro. Most preferably, R1, R2, R3, R4 and R5 are the same or different and are independently selected from H and linear or branched C1-C20-alkyl and Z is chloro.
Thus, it is preferred that one or more of R1, R2, R3, R4 and R5 is/are H and Z is chloro. Additionally or alternatively, it is preferred that one or more of R1, R2, R3, R4 and R5 is/are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl and Z is chloro. For example, one or more of R1, R2, R3, R4 and R5 is/are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl, and Z is chloro. It is especially preferred that one or more of R1, R2, R3, R4 and R5 is/are C1- or C2-alkyl, e.g. C1-alkyl, and Z is chloro.
Preferably, R1, R3 and R5 are the same and Z is chloro. In this embodiment, R1, R3 and R5 are preferably selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. Preferably, R1, R3 and R5 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. For example, R1, R3 and R5 are the same and are selected from linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro.
In one embodiment, R1, R3 and R5 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl, and Z is chloro. For example, R1, R3 and R5 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl, and Z is chloro. It is especially preferred that R1, R3 and R5 are the same and are C1- or C2-alkyl, e.g. C1-alkyl, and Z is chloro.
In one embodiment, R2 and R4 are the same and Z is chloro. In this embodiment, R2 and R4 are preferably selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. Preferably, R2 and R4 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. For example, R2 and R4 are the same and are selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro.
In one embodiment, R2 and R4 are the same and are H, and Z is chloro.
It is appreciated that R2 and R4 are preferably different from R1, R3 and R5. Thus, if R2 and R4 are different from R1, R3, and R5, R2 and R4 are preferably the same and are H and R1, R3 and R5 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl, and Z is chloro. For example, R2 and R4 are the same and are H and R1, R3 and R5 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl, and Z is chloro. It is especially preferred that R2 and R4 are the same and are H and R1, R3 and R5 are the same and are C1- or C2-alkyl, e.g. C1-alkyl, and Z is chloro.
As regards R7, R8, R9, R10 and R11 in the general formula 111b, it is to be noted that they can be the same or different. Preferably, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro.
In one embodiment, R7, R8, R9, R10 and R11 in the general formula IIIb are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and C6-C12-aryl, and Z is chloro. Preferably, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen and, linear or branched C1-C20-alkyl, and Z is chloro. Most preferably, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H and, linear or branched C1-C20-alkyl, and Z is chloro.
Thus, it is preferred that one or more of R7, R8, R9, R10 and R11 is/are H and Z is chloro.
Additionally or alternatively, it is preferred that one or more of R7, R8, R9, R10 and R11 is/are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear CI-C8-alkyl, and Z is chloro. For example, one or more of R7, R8, R9, R10 and R11 is/are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl, and Z is chloro. It is especially preferred that one or more of R7, R8, R9, R10 and R11 is/are C1- or C2-alkyl, e.g. C1-alkyl, and Z is chloro.
Preferably, R7, R9 and R11 are the same and Z is chloro. In this embodiment, R7, R9 and R11 are preferably selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-0u2-arylalkoxy, C9-C15-alkenylarylalkoxy, SR4, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. Preferably, R7, R9 and R11 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. For example, R7, R9 and R11 are the same and are selected from linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro.
In one embodiment, R7, R9 and R11 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl, and Z is chloro. For example, R7, R9 and R11 are the same and are linear or branched C1-C8-alkyl, e.g. linear C1-C8-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C8-alkyl, e.g. linear C1-C8-alkyl, and Z is chloro. It is especially preferred that R7, R9 and R11 are the same and are C1- or C2-alkyl, e.g. C1-alkyl, and Z is chloro.
In one embodiment, R8 and R10 are the same and Z is chloro. In this embodiment, R8 and R10 are preferably selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, SR14, NHR14 or NR14Ris with R14 and Ris being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. Preferably, R8 and R10 are selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro. For example, R8 and R10 are the same and are selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and Z is chloro.
In one embodiment, R8 and R10 are the same and are H and Z is chloro.
It is appreciated that R8 and R10 are preferably different from R7, R9 and R11. Thus, if R8 and R10 are different from R7, R9 and R11, R8 and R10 are preferably the same and are H and R7, R9 and R11 are the same and are linear or branched C1-C20-alkyl, preferably linear or branched C1-C18-alkyl, more preferably linear or branched C1-C12-alkyl and most preferably linear C1-C8-alkyl, e.g. linear C1-C8-alkyl, and Z is chloro. For example, R8 and R10 are the same and are H and R7, R9 and R11 are the same and are linear or branched C1-C6-alkyl, e.g. linear C1-C6-alkyl, preferably linear or branched C1-C4-alkyl, e.g. linear C1-C4-alkyl, and most preferably linear or branched C1-C3-alkyl, e.g. linear C1-C3-alkyl, and Z is chloro. It is especially preferred that R8 and R10 are the same and are H and R7, R9 and R11 are the same and are C1- or C2-alkyl, e.g. C1-alkyl, and Z is chloro.
In one embodiment, the mixture obtained in step a) is contacted with a compound of the general formula IIIa, wherein R1, R3 and R5 are the same and R2 and R4 are the same and Z is chloro. Preferably, R1, R3 and R5 in general formula IIIa are the same and are C1-alkyl and R2 and R4 are the same and are H and Z is chloro. It is appreciated that this embodiment specifically results in a mono(acyl)phosphine of the general formula I and/or the corresponding symmetric bis(acyl)phosphine of the general formula II, i.e. R1, R3, R5, R7, R9 and R11 are the same and R2, R4, R8 and R10 are the same.
Alternatively, the mixture obtained in step a) is contacted with a compound of the general formula IIIa and IIIB, in which R1, R3 and R5 in general formula IIIa are the same, R7, R9 and R11 in general formula IIIb are the same, R2 and R4 in general formula IIIa are the same and R8 and R10 in general formula IIIb are the same and Z is chloro. In this embodiment, R1, R3 and R5 in general formula IIIa are different from R7, R9 and R11 in general formula IIIb and R2 and R4 in general formula IIIa are different from R8 and R10 in general formula IIIb and Z is chloro. It is thus appreciated that a mixed bis(acyl)phosphine is obtained if compounds of the general formula IIIa and IIIB are added in step b) of the present process.
It is preferred that the equivalent weight ratio of the compound of the general formula IIIa and/or IIIB to the metal phosphide added in step a) [IIIa and/or IIIb:metal phosphide] is from 15:1 to 1:1, more preferably from 12:1 to 2:1, even more preferably from 10:1 to 2:1 and most preferably from 8:1 to 2:1.
Step b) of the process of the present invention can be carried out over a wide temperature range. Thus, process step b) is preferably carried out at a temperature in the range from −5 to 50° C., preferably in the range from 0 to 40° C., more preferably in the range from 0 to 30° C., and most preferably in the range from 0 to 28° C.
It is appreciated that the yield of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II obtained by the process can be increased if the temperature in process step b) is below or in the same range (±5° C.) as the temperature used in process step a). Thus, it is preferred that step b) is carried out at about room temperature, i.e. a temperature of about 21° C.±2° C.
In one embodiment, process steps a) and b) are carried out at about room temperature, i.e. a temperature of about 21° C.±2° C.
Alternatively, process step b) is carried out at a temperature below the temperature used in process step a).
In one embodiment, process step b) is carried out without the addition of further additives. Alternatively, one or more additives can be added to process step b). For example, an additive selected from the group comprising potassium tert-butoxide, trisodium α-DL-alanine diacetate, trimethylamine, triethylamine and mixtures thereof, can be added into step b).
Additionally or alternatively, an alcohol can be added into step b). The alcohol is preferably selected from the group comprising methanol, ethanol, n-propanol, iso-propanol, n-butanol, iso-butanol, tert-butanol, n-amyl alcohol, sec-amyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol, ethylenglycol, 1,2,3-propantriol, ethanolamine, diethanolamine, triethanolamine and mixtures thereof. The overall yield is further improved if a sterically hindered alcohol is added. Thus, the alcohol is especially selected from the group comprising tert-butanol, sec-amyl alcohol, tert-amyl alcohol, 3-methyl-3-pentanol and mixtures thereof. Most preferably, the alcohol is tert-butanol, tert-amyl alcohol, 3-methyl-3-pentanol and mixtures thereof. For example, the alcohol is tert-amyl alcohol or 3-methyl-3-pentanol.
If an alcohol is added in process step b), the alcohol is preferably added to the mixture of step a) before the compound of the general formula IIIa and/or IIIB is added.
Process step b) is preferably carried out under mixing the components, i.e. the mixture obtained in step a), the compound of the general formula IIIa and/or IIIB and optional additives and alcohol. The skilled person will adapt the mixing conditions (such as the configuration of mixing tools and mixing speed) according to his process equipment.
Subsequently to step b), the mixture obtained in step b) is acidified in step c). Preferably, step c) is carried out by adding an acid. It is preferred that the acid has a pKa value of below 6, more preferably in the range from 0 to 5, and most preferably in the range from 2 to 5.
In one embodiment, the acid is preferably selected from the group comprising hydrochloric acid, acetic acid, propionic acid, butanoic acid, oxalic acid, fumaric acid, benzoic acid, phosphoric acid, sulfuric acid, citric acid and mixtures thereof.
It is appreciated that the acid is not restricted to a specific acid, but it is preferred to add a weak acid in order to avoid the unwanted formation of by-products. Thus, the acid is preferably selected from acetic acid, propionic acid, butanoic acid, oxalic acid, fumaric acid, benzoic acid and citric acid, more preferably is acetic acid.
It is preferred that the equivalent weight ratio of the compound of the general formula IIIa and/or IIIB to the acid added in step c) [IIIa and/or IIIb:acid] is from 15:1 to 1:1, more preferably from 12:1 to 2:1, even more preferably from 10:1 to 2:1 and most preferably from 8:1 to 2:1.
Step c) of the process of the present invention can be carried out over a wide temperature range. Thus, process step b) is preferably carried out at a temperature in the range from −5 to 50° C., preferably in the range from 0 to 40° C., more preferably in the range from 0 to 30° C., and most preferably in the range from 0 to 28° C. However, it is preferred that step c) is carried out at about room temperature, i.e. a temperature of about 21° C.±2° C.
Subsequent to process step c) of acidifying the mixture obtained in step b), the process may comprise further steps for isolating and/or purifying the obtained mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II.
For example, the process may further comprise a step of
In one embodiment, the process further comprises the steps of
Additionally, the process may further comprise a step of drying the obtained mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II.
Such steps are well known in the art and will be adapted by the skilled person according to the process conditions and equipment used for carrying out the process of the present invention.
In one embodiment, the process comprises a further step d) of alkylating, alkoxylating, alkenylating, alkenoxylating, arylating, acylating, carboxylating, cycloalkylating, cycloalkoxylating, arylalkoxylating, alkenylarylalkoxylating or hydroxylating and oxidizing the bis(acyl)phosphine of the general formula II obtained in step c) for obtaining the bis(acyl)phosphine of the general formula IV
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are as defined above, and R12 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
With regard to the definition of the R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula IV and preferred embodiments thereof, reference is made to the statements provided above when discussing the technical details of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II obtained by the process of the present invention.
As regards R12 in general formula IV, it is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. Preferably, R12 is selected from the group comprising OH, linear or branched C1-C20-alkyl, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl,and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. More preferably, R12 is selected from the group comprising OH, linear or branched C1-C20-alkyl and C6-C12-aryl. Most preferably, R12 is OH or linear or branched C1-C20-alkyl. For example, R12 is OH.
The oxidizing is preferably carried out by using hydrogen peroxide.
Reactions resulting in the alkylating, alkoxylating, alkenylating, alkenoxylating, arylating, acylating, carboxylating, cycloalkylating, cycloalkoxylating, arylalkoxylating, alkenylarylalkoxylating or hydroxylating and oxidizing of a bis(acyl)phosphine of the general formula II are well known in the art and can be adapted by the skilled person according to the specific reaction and equipment used for carrying out the process of the present invention.
Alternatively, the process can comprise a further step d) of alkylating, alkoxylating, alkenylating, alkenoxylating, arylating, acylating, carboxylating, cycloalkylating, cycloalkoxylating, arylalkoxylating, alkenylarylalkoxylating or hydroxylating the mono(acyl)phosphine of the general formula I obtained in step c) for obtaining the mono(acyl)phosphine of the general formula V
wherein R1, R2, R3, R4 and R5 are as defined above, and R13 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring.
With regard to the definition of the R1, R2, R3, R4 and R5 in general formula V and preferred embodiments thereof, reference is made to the statements provided above when discussing the technical details of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II obtained by the process of the present invention.
As regards R13 in general formula V, it is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. Preferably, R13 is selected from the group comprising OH, linear or branched C1-C20-alkyl, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. More preferably, R13 is selected from the group comprising OH, linear or branched C1-C20-alkyl and C6-C12-aryl.
Reactions resulting in the alkylating, alkoxylating, alkenylating, alkenoxylating, arylating, acylating, carboxylating, cycloalkylating, cycloalkoxylating, arylalkoxylating, alkenylarylalkoxylating or hydroxylating of a mono(acyl)phosphine of the general formula I are well known in the art and can be adapted by the skilled person according to the specific reaction and equipment used for carrying out the process of the present invention.
In another aspect, the present invention refers to a mono(acyl)phosphine of the general formula I and/or a bis(acyl)phosphine of the general formula II,
wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring;
R6 is H or R6 is replaced by an alkaline earth metal cation or a mixed alkali metal/alkaline earth metal cation;
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. The mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II is preferably obtained by the process of the present invention.
With regard to the definition of the R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 in general formula I and/or II and preferred embodiments thereof, reference is made to the statements provided above when discussing the technical details of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II obtained by the process of the present invention.
In a further aspect, the present invention refers to a bis(acyl)phosphine of the general formula IV
wherein R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and R12 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C18-alkenylarylalkoxy and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. The bis(acyl)phosphine of the general formula IV is preferably obtained by the process of the present invention.
With regard to the definition of the R1, R2, R3, R4, R5, R7, R8, R9, R10 and R11 in general formula IV and preferred embodiments thereof, reference is made to the statements provided above when discussing the technical details of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II and the bis(acyl)phosphine of the general formula IV obtained by the process of the present invention.
In a further aspect, the present invention refers to a mono(acyl)phosphine of the general formula V
wherein R1, R2, R3, R4 and R5 are the same or different and are independently selected from H, halogen, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15-alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl, SR14, NHR14 or NR14R15 with R14 and R15 being independently selected from H, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl and C3-C8-cycloalkyl, and an O-, S- or N-containing 5- or 6-membered heterocyclic ring, and R13 is selected from the group comprising OH, linear or branched C1-C20-alkyl, linear or branched C2-C8-alkenyl, C1-C8-alkoxy, C2-C8-alkenyloxy, C3-C8-cycloalkyl, C6-C12-aryl, C1-C8-acyl, C3-C8-cycloalkoxy, C7-C12-arylalkoxy, C9-C15- alkenylarylalkoxy, nitro-, C6-C12-arylsulfonyl, 4-alkylarylsulfonyl, C1-C20-alkylcarboxy, C1-C8-alkoxycarbonyl and an O-, S- or N-containing 5- or 6-membered heterocyclic ring. The mono(acyl)phosphine of the general formula V is preferably obtained by the process of the present invention.
With regard to the definition of the R1, R2, R3, R4, R5 and R13 in general formula V and preferred embodiments thereof, reference is made to the statements provided above when discussing the technical details of the mono(acyl)phosphine of the general formula I and/or the bis(acyl)phosphine of the general formula II and the mono(acyl)phosphine of the general formula V obtained by the process of the present invention.
The scope and interest of the invention will be better understood based on the following examples which are intended to illustrate certain embodiments of the invention and are non-limitative.
Synthetic Procedure
A 100 mL flask was flushed with argon and charged with calcium phosphide (8%, 3.1g, 1.36 mmol, 1 eq.). Dry 1,2-dimethoxyethane (DME) (20 mL) was added to the flask. After stirring the reaction mixture for 15 minutes, 2,4,6-trimethylbenzoyl chloride (1.0 g, 0.909 mL, 5.55 mmol, 4 eq.) was added slowly over a period of 10 minutes at ambient temperature (21° C.). Subsequently, the mixture was stirred for another 17 hours at ambient temperature. A color change from red-brown to greenish yellow was observed, along with an increase of the viscosity of the mixture. This protocol yields the calcium salt Ca[P(COMes)2]2 as the product. This was further treated at room temperature (22° C.) with acetic acid (1.12 g, 19 mmol, 13.7 eq.) which was added dropwise within 10 minutes. The reaction mixture was stirred for another 22 hours at ambient temperature to yield HP(COMes)2 (BAP-H).
The solvent DME was removed in vacuo and a yellow solid residue was obtained. The yellow solid was dissolved in dry toluene (75 mL) and filtered over celite in order to remove CaCl2 and Ca(OAc)2. The filter cake was washed twice with dry toluene (2×5 mL). After filtration, toluene was removed in vacuo at room temperature (24° C.) for 6 hours and gave 5.4 g of crude BAP-H (3.5% purity based on NMR spectroscopy which corresponds to a yield of 21.3%.
The 31P{1H} NMR spectrum shows two signals at δ=81 and 6 ppm indicating an equilibrium of the protonated phosphine (δ=6 ppm) and its enol from P-acyl-2-hydroxy-phosphaalkene (δ=81 ppm) as shown in the following scheme 1:
Formula: C20H23O2P
Molar mass: 326.37 g/mol
31P NMR (121.5 MHz, C6D6) δ [ppm]=81 (s), 6 (s).
1H NMR (400.13 MHz, C6D6) δ [ppm]=2.00 (s, 6H, Mes p-CH3) 2.33 (s, 12H, Mes o-CH3), 6.55 (s, 4H, Mes m-H).
| Number | Date | Country | Kind |
|---|---|---|---|
| 17173445.2 | May 2017 | EP | regional |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/EP2018/064156 | 5/30/2018 | WO | 00 |
